Stock Analiz

Profound Medical Corp. PROF

Medical/Dental Instruments · data as of November 13, 2026

$7.42Market cap $272M
Open the interactive analysis →

Profound Medical Corp. (PROF) is a healthcare company listed in the US with a market value of about $272M. In the twelve months to September 30, 2026 it had revenue of $24M and net income of -$32M, a net margin of -137.5%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 17% a year, a 5-year average ROIC of -48%.

About Profound Medical

Profound Medical is listed in the US and classified in medical/dental instruments. Revenue went from $4M in 2019 to $16M in 2025, growth of about 25.2% a year. It was profitable in 0 of the last 7 years in our data. It spends 128% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S11.5
P/B6.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-11.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)50.7%
Revenue growth (5 yrs, per year)17.1%
EPS growth (5 yrs, per year)2.4%
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-358.8%
ROIC (5-yr avg.)-48.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$24M$16M$11M$7M$7M$7M$7M$4M
Net income-$32M-$43M-$28M-$28M-$29M-$31M-$22M-$15M
Free cash flow-$32M-$38M———-$22M——
EPS (diluted)$-0.94$-1.16$-0.76$-0.77$-0.78$-0.84$-0.59$-0.42
Net margin-137.5%-264.4%-260.4%-393.4%-429.1%-446.7%-296.0%-364.7%
ROIC—-45.8%-50.4%-73.0%-42.5%-29.7%-15.3%-50.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $11.14, 50% above the current price; targets range from $10.00 to $12.00; the consensus rating is “Strong buy”; expected EPS is $-0.93 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Profound Medical pay a dividend?

Not currently.

Is Profound Medical a good stock to buy?

We do not give buy or sell advice. Profound Medical scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.